Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
seekingalpha.comSana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 10
prnewswire.comDid Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?prnewswire.comJun 2
globenewswire.comSana Biotechnology to Present at June 2026 Investor Conferencesglobenewswire.comMay 27
globenewswire.comSana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facilityglobenewswire.comMay 15
seekingalpha.comSana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.comMay 13